Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta‐analysis

医学 米兰标准 肝细胞癌 肝移植 优势比 内科学 胃肠病学 置信区间 随机对照试验 移植 外科
作者
Benjamin Menahem,Jean Lubrano,Christophe Duvoux,A. Mulliri,Arnaud Alvès,Charlotte Costentin,Ariane Mallat,Guy Launoy,Alexis Laurent
出处
期刊:Liver Transplantation [Lippincott Williams & Wilkins]
卷期号:23 (6): 836-844 被引量:96
标识
DOI:10.1002/lt.24758
摘要

This meta‐analysis compared the effects of liver transplantation (LT) and liver resection (LR) on overall survival (OS) and disease‐free survival (DFS) in patients with hepatocellular carcinoma (HCC) small transplantable HCC or within Milan criteria. Articles comparing LR with LT for HCC, based on Milan criteria or small size, published up to June 2015 were selected, and a meta‐analysis was performed. No randomized controlled trial has been published to date comparing survival outcomes in patients with HCC who underwent LR and LT. Nine studies were identified, including 570 patients who underwent LR and 861 who underwent LT. For HCC within the Milan criteria, the 1‐year OS rates following LR and LT were 84.5% (473/560) and 84.4% (710/841), respectively (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.71‐1.33; P = 0.8), and the 5‐year OS rates were 47.9% (273/570) and 59.3% (509/858), respectively (OR, 0.60; 95% CI, 0.35‐1.02; P = 0.06). One‐year DFS rates were similar (OR, 1.00; 95% CI, 0.39‐2.61; P = 1.00), whereas the 3‐year DFS rate was significantly lower in the LR group (54.4%, 210/386) than in the LT group (74.2%, 317/427; OR, 0.24; 95% CI, 0.07‐0.80; P = 0.02), and the 5‐year DFS rate was significantly lower for LR than LT (OR, 0.18; 95% CI, 0.06‐0.53; P < 0.01). For small HCCs, the 5‐year OS rate was significantly lower for patients who underwent LR than LT (OR, 0.30; 95% CI, 0.19‐0.48; P < 0.001). In conclusion, relative to LR, LT in patients with HCC meeting the Milan criteria had no benefits before 10 years for OS. For DFS, the benefit is obtained after 3 years. Liver Transplantation 23 836–844 2017 AASLD .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
机灵雅寒完成签到 ,获得积分10
刚刚
丛玉林发布了新的文献求助10
刚刚
刚刚
拾一发布了新的文献求助10
1秒前
科研通AI5应助丁青采纳,获得10
1秒前
asewr发布了新的文献求助10
1秒前
小马甲应助wen采纳,获得10
2秒前
科研通AI5应助MOON采纳,获得30
4秒前
答辩发布了新的文献求助10
4秒前
格物致知发布了新的文献求助10
5秒前
6秒前
系统提示完成签到,获得积分10
7秒前
7秒前
8秒前
CipherSage应助专注的班采纳,获得10
8秒前
隐形曼青应助zhonghbush采纳,获得10
8秒前
成就映秋完成签到,获得积分10
9秒前
阅读何必理解完成签到,获得积分10
10秒前
10秒前
Intrepid_jay发布了新的文献求助10
10秒前
11秒前
柑橘乌云完成签到,获得积分10
12秒前
pluto应助ChenhaoTong采纳,获得10
12秒前
希望天下0贩的0应助pka采纳,获得10
12秒前
思源应助科研通管家采纳,获得10
12秒前
芳蔼应助科研通管家采纳,获得10
12秒前
12秒前
脑洞疼应助科研通管家采纳,获得10
12秒前
12秒前
搜集达人应助科研通管家采纳,获得10
12秒前
Akim应助科研通管家采纳,获得10
12秒前
科研通AI5应助muyige采纳,获得10
12秒前
天天快乐应助科研通管家采纳,获得10
12秒前
彭于晏应助科研通管家采纳,获得10
12秒前
Jasper应助科研通管家采纳,获得30
13秒前
脑洞疼应助科研通管家采纳,获得10
13秒前
传奇3应助科研通管家采纳,获得10
13秒前
答辩完成签到 ,获得积分10
13秒前
在水一方应助科研通管家采纳,获得10
13秒前
香蕉觅云应助科研通管家采纳,获得10
13秒前
高分求助中
All the Birds of the World 4000
Production Logging: Theoretical and Interpretive Elements 3000
Machine Learning Methods in Geoscience 1000
Weirder than Sci-fi: Speculative Practice in Art and Finance 960
Resilience of a Nation: A History of the Military in Rwanda 888
Essentials of Performance Analysis in Sport 500
Measure Mean Linear Intercept 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3727349
求助须知:如何正确求助?哪些是违规求助? 3272309
关于积分的说明 9976640
捐赠科研通 2987631
什么是DOI,文献DOI怎么找? 1639126
邀请新用户注册赠送积分活动 778475
科研通“疑难数据库(出版商)”最低求助积分说明 747670